An Intelligence-Driven Approach To Partnering
An Interview With A Rising Leader, C4X Discovery's Bhavna Hunjan
Her experience in banking and consultancy helped C4XD strategy chief Bhavna Hunjan to build a team that drives corporate development through partnerships, with a focus on attractive preclinical data packages to out-license to pharmaceutical companies.
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.
The timeline for a US resubmission of the closely watched PCSK9-targeting cholesterol treatment could be either Q2 or Q3 and approval will depend on whether the FDA needs to make a physical inspection of an Italian facility.